Gastric Inhibitory Polypeptide Receptor Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR INDUSTRY

2.1 Summary about Gastric Inhibitory Polypeptide Receptor Industry

2.2 Gastric Inhibitory Polypeptide Receptor Market Trends

2.2.1 Gastric Inhibitory Polypeptide Receptor Production & Consumption Trends

2.2.2 Gastric Inhibitory Polypeptide Receptor Demand Structure Trends

2.3 Gastric Inhibitory Polypeptide Receptor Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 HM-15211

4.2.2 LBT-6030

4.2.3 LY-3298176

4.2.4 NNC-92041706

4.2.5 Others

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Metabolic Disorder

4.3.2 Type 2 Diabetes

4.3.3 Obesity

4.3.4 Others

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 HM-15211

5.2.2 LBT-6030

5.2.3 LY-3298176

5.2.4 NNC-92041706

5.2.5 Others

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Metabolic Disorder

5.3.2 Type 2 Diabetes

5.3.3 Obesity

5.3.4 Others

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 HM-15211

6.2.2 LBT-6030

6.2.3 LY-3298176

6.2.4 NNC-92041706

6.2.5 Others

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Metabolic Disorder

6.3.2 Type 2 Diabetes

6.3.3 Obesity

6.3.4 Others

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 HM-15211

7.2.2 LBT-6030

7.2.3 LY-3298176

7.2.4 NNC-92041706

7.2.5 Others

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Metabolic Disorder

7.3.2 Type 2 Diabetes

7.3.3 Obesity

7.3.4 Others

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 HM-15211

8.2.2 LBT-6030

8.2.3 LY-3298176

8.2.4 NNC-92041706

8.2.5 Others

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Metabolic Disorder

8.3.2 Type 2 Diabetes

8.3.3 Obesity

8.3.4 Others

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 HM-15211

9.2.2 LBT-6030

9.2.3 LY-3298176

9.2.4 NNC-92041706

9.2.5 Others

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Metabolic Disorder

9.3.2 Type 2 Diabetes

9.3.3 Obesity

9.3.4 Others

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Alchemia Limited

10.1.2 AstraZeneca Plc

10.1.3 Carmot Therapeutics, Inc.

10.1.4 Diabetica Limited

10.1.5 Longevity Biotech, Inc

10.1.6 Novo Nordisk A/S

10.1.7 Sanofi

10.1.8 Zealand Pharma A/S

10.2 Gastric Inhibitory Polypeptide Receptor Sales Date of Major Players (2017-2020e)

10.2.1 Alchemia Limited

10.2.2 AstraZeneca Plc

10.2.3 Carmot Therapeutics, Inc.

10.2.4 Diabetica Limited

10.2.5 Longevity Biotech, Inc

10.2.6 Novo Nordisk A/S

10.2.7 Sanofi

10.2.8 Zealand Pharma A/S

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

1.Table Gastric Inhibitory Polypeptide Receptor Product Type Overview

2.Table Gastric Inhibitory Polypeptide Receptor Product Type Market Share List

3.Table Gastric Inhibitory Polypeptide Receptor Product Type of Major Players

4.Table Brief Introduction of Alchemia Limited

5.Table Brief Introduction of AstraZeneca Plc

6.Table Brief Introduction of Carmot Therapeutics, Inc.

7.Table Brief Introduction of Diabetica Limited

8.Table Brief Introduction of Longevity Biotech, Inc

9.Table Brief Introduction of Novo Nordisk A/S

10.Table Brief Introduction of Sanofi

11.Table Brief Introduction of Zealand Pharma A/S

12.Table Products & Services of Alchemia Limited

13.Table Products & Services of AstraZeneca Plc

14.Table Products & Services of Carmot Therapeutics, Inc.

15.Table Products & Services of Diabetica Limited

16.Table Products & Services of Longevity Biotech, Inc

17.Table Products & Services of Novo Nordisk A/S

18.Table Products & Services of Sanofi

19.Table Products & Services of Zealand Pharma A/S

20.Table Market Distribution of Major Players

21.Table Global Major Players Sales Revenue (Million USD) 2017-2020e

22.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

23.Table Global Gastric Inhibitory Polypeptide Receptor Market Forecast (Million USD) by Region 2021f-2026f

24.Table Global Gastric Inhibitory Polypeptide Receptor Market Forecast (Million USD) Share by Region 2021f-2026f

25.Table Global Gastric Inhibitory Polypeptide Receptor Market Forecast (Million USD) by Demand 2021f-2026f

26.Table Global Gastric Inhibitory Polypeptide Receptor Market Forecast (Million USD) Share by Demand 2021f-2026f